中博瑞康 is a provider of cell immunotherapy products and testing services targeting tumors, cardiovascular and cerebrovascular diseases, immune diseases and age-related conditions. The company has developed multiple cell immunotherapy products based on ACTL (targeted antitumor cell immunity) and EAAL (amplified activated autologous lymphocyte) technologies. It also offers tumor antigen testing and early cancer screening services including circulating tumor cell and circulating tumor DNA detection. The firm’s offerings span screening, diagnosis, treatment and health management. Recent financing will be used to build a modern production system, strengthen R&D and global registration capabilities, and accelerate expansion into key global markets.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2024